ライフサイエンスコーパス: dacarbazine

1 andard-of-care chemotherapy (temozolomide or dacarbazine).

2 omly assigned, 269 to binimetinib and 133 to dacarbazine.

3 -up, adriamycin, bleomycin, vinblastine, and dacarbazine.

4 se rates were 48% for vemurafenib and 5% for dacarbazine.

5 w that it is no more effective than standard dacarbazine.

6 rs may potentiate the therapeutic effects of dacarbazine.

7 ne (BCNU), temozolomide, streptozotocin, and dacarbazine.

8 ted with the Dartmouth regimen compared with dacarbazine.

9 d eribulin and 218 (97%) of 224 who received dacarbazine.

10 th nivolumab and 17.6% of those treated with dacarbazine.

11 th those who initially received placebo plus dacarbazine.

12 ed to receive vemurafenib and 338 to receive dacarbazine.

13 d acquired resistance to B-Raf inhibition or dacarbazine.

14 on vemurafenib and 9.5 months (3.1-14.7) on dacarbazine.

15 nificantly superior OS and PFS compared with dacarbazine.

16 murafenib and 287 patients were treated with dacarbazine.

17 agents include doxorubicin, ifosfamide, and dacarbazine.

18 er cycle, and tamoxifen 10 mg orally bid) or dacarbazine 1, 000 mg/m(2).

19 or investigator's choice chemotherapy (ICC; dacarbazine 1,000 mg/m(2) every 3 weeks or carboplatin a

20 21-day cycle, patients received intravenous dacarbazine 1,000 mg/m(2) for a maximum of 16 cycles.

21 n of nivolumab 3 mg/kg every 2 weeks or ICC (dacarbazine 1000 mg/m(2) every 3 weeks or paclitaxel 175

22 ther binimetinib 45 mg orally twice daily or dacarbazine 1000 mg/m(2) intravenously every 3 weeks.

23 inib (2 mg orally) once daily or intravenous dacarbazine (1000 mg per square meter of body-surface ar

24 r vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface ar

25 r vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg/m(2) of body surface area intraveno

26 g/m2 orally daily for 5 of every 28 days, or dacarbazine, 1000 mg/m2 intravenously every 21 days [inv

27 ith dacarbazine (median OS for trabectedin v dacarbazine, 12.4 v 12.9 months; hazard ratio, 0.87; P =

28 bulin (152 [67%]) than in those who received dacarbazine (126 [56%]), as were deaths (10 [4%] vs 3 [1

29 PFS was also improved with eribulin versus dacarbazine (2.9 v 1.7 months, respectively; hazard rati

30 randomized to receive the Dartmouth regimen (dacarbazine 220 mg/m(2) and cisplatin 25 mg/m(2) days 1

31 eived combination cisplatin (25 mg/m2/d) and dacarbazine (220 mg/m2/d) on days 1 through 3 and 22 thr

32 th dacarbazine (median PFS for trabectedin v dacarbazine, 4.2 v 1.5 months; hazard ratio, 0.55; P < .

33 ollowing: cisplatin 20 mg/m2 on days 1 to 4, dacarbazine 800 mg/m2 on day 1 only, vinblastine 1.6 mg/

34 .4 mg/m(2) intravenously on days 1 and 8) or dacarbazine (850 mg/m(2), 1000 mg/m(2), or 1200 mg/m(2)

35 .4 mg/m(2) intravenously on days 1 and 8) or dacarbazine (850, 1,000, or 1,200 mg/m(2) intravenously

36 cles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) alone or 6 cycles of ABVD followed by

37 ith doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone or to treatment with subtotal n

38 ls, doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and mechlorethamine, vincristine, pro

39 ing doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and Stanford V regimens in locally ex

40 of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and was labeled PET2.

41 and after 2 adriamycin-bleomycin-vinblastine-dacarbazine (ABVD) courses with (18)F-FDG PET, enrolled

42 or doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in C studies; and VbM (reduced dose o

43 of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in previously untreated-according to

44 ith doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in the HAART era according to HIV ser

45 rubicin, bleomycin, vinblastine sulfate, and dacarbazine (ABVD) is associated with severe toxicity in

46 with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or equivalent regimens, the 5-year FF

47 cles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) plus 20 Gy involved-field (IF)-RT to

48 ith doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) require radiotherapy.

49 cles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) to guide treatment modification in a

50 ith doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) were enrolled retrospectively from ce

51 red doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with mechlorethamine, doxorubicin, vi

52 ved doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)-like chemotherapy.

53 ion doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

54 three preoperative cycles of doxorubicin and dacarbazine (ADIC), cyclophosphamide and ADIC (CyADIC),

55 = 252) at weeks 1, 4, 7, and 10 followed by dacarbazine alone every 3 weeks through week 22.

56 progression-free survival when compared with dacarbazine alone.

57 nt has proven to be superior to single agent dacarbazine alone.

58 Treatment with dacarbazine also increased stomach cancer risk (12 cases

59 Temozolomide, an oral analog of dacarbazine, also has activity against NETs when adminis

60 progression-free survival, as compared with dacarbazine, among previously untreated patients who had

61 eribulin with that in patients who received dacarbazine (an active control).

62 edian, 51.3 v 45.6 weeks in the placebo plus dacarbazine and sorafenib plus dacarbazine arms, respect

63 oved progression-free survival compared with dacarbazine and was tolerable.

64 BVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and 30 Gy involved-field radiotherapy (IFRT

65 sks were seen for doxorubicin, dactinomycin, dacarbazine, and carmustine.

66 sed in vitro to increasing concentrations of dacarbazine, and dacarbazine-resistant cell lines SB2-D

67 anomas to the alkylating drugs temozolomide, dacarbazine, and fotemustine.

68 weeks versus 11.7 weeks in the placebo plus dacarbazine arm (hazard ratio [HR], 0.665; P = .068).

69 Median PFS in the sorafenib plus dacarbazine arm was 21.1 weeks versus 11.7 weeks in the

70 s; HR, 0.619) in favor of the sorafenib plus dacarbazine arm.

71 placebo plus dacarbazine and sorafenib plus dacarbazine arms, respectively; HR, 1.022).

72 ge, doxorubicin, bleomycin, vinblastine, and dacarbazine as initial therapy, and granulocyte colony-s

73 egimens in metastatic melanoma that included dacarbazine as the control arm, and which reported both

74 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as compared with standard combined-modality

75 acarbazine-matched placebo every 3 weeks) or dacarbazine (at a dose of 1000 mg per square meter of bo

76 ve cooperativity with the frontline regimens dacarbazine, B-Raf inhibition, and the anti-CTLA-4 antib

77 ubicin (Adriamycin), bleomycin, vinblastine, dacarbazine chemotherapy along with involved-field radio

78 ard doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy in the ongoing intergroup trial

79 tandard doxorubicin, bleomycin, vinblastine, dacarbazine chemotherapy regimen, prescribed for nearly

80 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy is regarded as standard of car

81 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy, and then underwent an interim

82 ls have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen) can i

83 either HDI or biochemotherapy consisting of dacarbazine, cisplatin, vinblastine, interleukin-2, IFN

84 s a robust surrogate for overall survival in dacarbazine-controlled randomised trials of metastatic m

85 Treatment of melanoma patients with dacarbazine could select for a more aggressive melanoma

86 338 patients initially randomly assigned to dacarbazine crossed over from dacarbazine to vemurafenib

87 igned to receive cisplatin, vinblastine, and dacarbazine (CVD) either alone or concurrent with interl

88 of chemotherapy (cisplatin, vinblastine, and dacarbazine [CVD]) with those of sequential biochemother

89 ith doxorubicin, bleomycin, vinblastine, and dacarbazine; cyclophosphamide, vincristine, procarbazine

90 CVD consisted of dacarbazine (days 1 and 22) and cisplatin and vinblastin

91 ion regimen included cisplatin, vinblastine, dacarbazine, decrescendo interleukin-2 (IL-2), and inter

92 ng to presence of crossover, trial size, and dacarbazine dose.

93 clinically relevant chemotherapeutic drugs (dacarbazine, doxorubicin, paclitaxel, cisplatin, gemcita

94 ineoplastic agents 5-fluorouracil (5-FU) and dacarbazine (DTIC) sensitize melanoma cells to lysis of

95 Patients crossed over to the dacarbazine (DTIC) treatment after disease progression f

96 erapy (results previously reported), BV plus dacarbazine (DTIC), and BV plus bendamustine.

97 the three-agent regimen of cisplatin (CDDP), dacarbazine (DTIC), and carmustine (BCNU) significantly

98 The combination of carmustine (BCNU), dacarbazine (DTIC), cisplatin (DDP), and tamoxifen (Tam)

99 d with matched control patients treated with dacarbazine (DTIC), median overall survival of 15.0 vers

100 py (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vinblastine, and pre

101 was both more effective and less costly than dacarbazine followed by IPI then NIVO, or IPI followed b

102 of doxorubicin, bleomycin, vinblastine, and dacarbazine followed by RT is rare.

103 n (BV) and AVD (adriamycin, vinblastine, and dacarbazine) followed by 30 Gy involved site radiation t

104 of doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin disease (HD) and had undergone 4

105 b-ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreated classical Hodgkin

106 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine), four escalated plus two standard cycles of

107 longer in the vemurafenib group than in the dacarbazine group (13.6 months [95% CI 12.0-15.2] vs 9.7

108 etinib group and 1.5 months (1.5-1.7) in the dacarbazine group (hazard ratio 0.62 [95% CI 0.47-0.80];

109 the nivolumab group versus 2.2 months in the dacarbazine group (hazard ratio for death or progression

110 red with 42.1% (95% CI, 33.0 to 50.9) in the dacarbazine group (hazard ratio for death, 0.42; 99.79%

111 ) compared with 7.6 months (6.1-16.6) in the dacarbazine group (HR 0.43 [95% CI 0.21-0.90]; p=0.024);

112 compared with 10.0 months (8.0-14.0) in the dacarbazine group (HR 0.75 [95% CI 0.60-0.93]; p=0.0085)

113 up versus 13.9% (95% CI, 9.5 to 19.4) in the dacarbazine group (odds ratio, 4.06; P<0.001).

114 the vemurafenib group and seven (2%) in the dacarbazine group had grade 5 events.

115 the binimetinib group vs none of 114 in the dacarbazine group), hypertension (20 [7%] vs two [2%]),

116 enib group and 64% (95% CI, 56 to 73) in the dacarbazine group.

117 nimetinib group and 25 (22%) patients in the dacarbazine group.

118 neutropenia (26 [9%] of 287 patients) in the dacarbazine group.

119 bocytopenia were increased in the oblimersen-dacarbazine group; however, there was no increase in ser

120 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine) has been established as the standard of car

121 ion on or after BCT (cisplatin, vinblastine, dacarbazine, IL-2 9 MU/m(2)/d for 4 days, and interferon

122 ed clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, m

123 superior disease control versus conventional dacarbazine in patients who have advanced liposarcoma an

124 se A phase III study comparing eribulin with dacarbazine in patients with advanced liposarcoma (LPS)

125 hase III trial to compare trabectedin versus dacarbazine in patients with advanced liposarcoma or lei

126 ed the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma.

127 the MEK inhibitor binimetinib versus that of dacarbazine in patients with advanced NRAS-mutant melano

128 fficacy and safety of eribulin compared with dacarbazine in patients with LPS, an independently rando

129 on of B-cell lymphoma 2 (Bcl-2) antisense to dacarbazine in the treatment of metastatic melanoma demo

130 biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2 (IL-2), and interferon alfa a

131 ned in a 2:1 ratio to receive trabectedin or dacarbazine intravenously every 3 weeks.

132 Dacarbazine is considered the gold standard for treatmen

133 ditional survival benefit of ipilimumab plus dacarbazine is maintained with twice as many patients al

134 modified mesna, doxorubicin, ifosfamide, and dacarbazine [MAID]), interdigitated preoperative radiati

135 er kilogram of body weight every 2 weeks and dacarbazine-matched placebo every 3 weeks) or dacarbazin

136 to eribulin compared with those assigned to dacarbazine (median 13.5 months [95% CI 10.9-15.6] vs 11

137 f death in the trabectedin arm compared with dacarbazine (median OS for trabectedin v dacarbazine, 12

138 f disease progression or death compared with dacarbazine (median PFS for trabectedin v dacarbazine, 4

139 metastatic melanoma, interleukin (IL)-2 and dacarbazine, mediate objective response rates of 12% to

140 assigned to either trabectedin (n = 345) or dacarbazine (n = 173).

141 d 1:1 to receive ipilimumab at 10 mg/kg plus dacarbazine (n = 250) or placebo plus dacarbazine (n = 2

142 g plus dacarbazine (n = 250) or placebo plus dacarbazine (n = 252) at weeks 1, 4, 7, and 10 followed

143 total of 101 patients received placebo plus dacarbazine (n = 50) or sorafenib plus dacarbazine (n =

144 plus dacarbazine (n = 50) or sorafenib plus dacarbazine (n = 51).

145 mly assigned patients to eribulin (n=228) or dacarbazine (n=224).

146 ib was associated with risk reduction versus dacarbazine of both death and progression in patients wi

147 ents with melanoma who had been treated with dacarbazine, one of the most frequently used chemotherap

148 ith doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens (P =.7 by log-rank te

149 herapy composed of tamoxifen, cisplatin, and dacarbazine or this same chemotherapy followed by interf

150 of doxorubicin, bleomycin, vinblastine, and dacarbazine (or equivalent).

151 ycin, 6 mg/m(2) vinblastine, and 375 mg/m(2) dacarbazine) or AVD (ABVD modified regimen without the i

152 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or both regimens, generally have a poor pr

153 l plus carboplatin, paclitaxel, carboplatin, dacarbazine, or oral temozolomide).

154 platinum II (cDDP, cis-platin), carboplatin, dacarbazine, or temozolomide together with velaparib, an

155 ne, doxorubicin, bleomycin, vinblastine, and dacarbazine; or standard BEACOPP (P = .0066).

156 2.8%) for patients treated with placebo plus dacarbazine (P = .002).

157 ath or disease progression, as compared with dacarbazine (P<0.001 for both comparisons).

158 ard doxorubicin, bleomycin, vinblastine, and dacarbazine (RABVD) in patients with classical Hodgkin l

159 Dacarbazine remains the reference standard treatment for

160 The dacarbazine-resistant cell lines SB2-D and MeWo-D exhibi

161 ncreasing concentrations of dacarbazine, and dacarbazine-resistant cell lines SB2-D and MeWo-D were s

162 0.35 to 0.75; P < .001) with eribulin versus dacarbazine, respectively.

163 osure of primary cutaneous melanoma cells to dacarbazine resulted in the upregulation of interleukin-

164 In a previous study, dacarbazine showed selective in vitro toxicity to sinuso

165 kinase inhibitor vemurafenib, compared with dacarbazine, shows improved response rates, progression-

166 The addition of oblimersen to dacarbazine significantly improved multiple clinical out

167 Dacarbazine significantly reduced tumor size in these mi

168 tudies with azathioprine, monocrotaline, and dacarbazine suggested that toxins that cause HVOD initia

169 IC20-50) of DNA-damaging drugs (doxorubicin, dacarbazine, temozolamide) or antimitotic drugs (paclita

170 rior therapies for active disease, including dacarbazine/temozolomide or interleukin-2 (IL-2).

171 and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.

172 ly assigned to dacarbazine crossed over from dacarbazine to vemurafenib.

173 duce doxorubicin, bleomycin, vinblastine and dacarbazine toxicity, the Cancer and Leukemia Group B co

174 icity of the Dartmouth regimen with standard dacarbazine treatment in stage IV melanoma patients.

175 Compared with the first-line dacarbazine treatment strategy, NIVO followed by IPI pro

176 th Epo significantly increased resistance to dacarbazine treatment, and Epo increased the phosphoryla

177 %) for patients treated with ipilimumab plus dacarbazine versus 8.8% (95% CI, 5.7% to 12.8%) for pati

178 dified concurrent biochemotherapy regimen of dacarbazine, vinblastine, cisplatin, decrescendo IL-2, i

179 The response rate to dacarbazine was 10.2% compared with 18.5% for the Dartmo

180 Tumor response to two cycles of dacarbazine was assessed on the basis of tumor size in o

181 The survival benefit with nivolumab versus dacarbazine was observed across prespecified subgroups,

182 Sorafenib plus dacarbazine was well tolerated in patients with advanced

183 or single agent outpatient regimens, such as dacarbazine, which is usually not effective in patients

184 ing doxorubicin, bleomycin, vinblastine, and dacarbazine with the Stanford V regimen has been initiat

185 VD (doxorubicin, bleomycin, vinblastine, and dacarbazine) with IFRT.

186 how long-term exposure of melanoma cells to dacarbazine would affect their tumorigenic and metastati

187 omly assigned, the addition of oblimersen to dacarbazine yielded a trend toward improved survival at